Athira Pharma to Present at Upcoming November Investor Conferences
11/10/2020 - 07:30 AM
SEATTLE, Nov. 10, 2020 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ: ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and stop neurodegeneration, today announced that Dr. Leen Kawas, President and Chief Executive Officer, and Dr. Hans Moebius, Chief Medical Officer, will participate in fireside chats at two upcoming investor conferences:
Stifel 2020 Virtual Healthcare Conference: Wednesday, November 18, 2020 at 2:40 pm ET Jefferies Virtual London Healthcare Conference: Thursday, November 19, 2020 at 2:20 pm ET A live webcast of each presentation can be accessed from the Investors section of the Athira website at https://investors.athira.com/news-and-events/events-and-presentations . An archived replay of each webcast will also be available on the company website for 90 days following the presentations.
About Athira Pharma , Inc. www.athira.com . You can also follow Athira on Facebook , LinkedIn and @athirapharma on Twitter and Instagram .
Investor & Media Contact :Julie.rathbun@athira.com
ATHA Rankings
#4750 Ranked by Stock Gains
ATHA Stock Data
Industry
Biological Product (except Diagnostic) Manufacturing
Sector
Manufacturing
Tags
Commercial Services, Miscellaneous Commercial Services, Health Technology, Biotechnology, Manufacturing, Medicinal and Botanical Manufacturing
About ATHA
m3 biotechnology is an innovative therapeutics company that has a novel platform of disease-modifying regenerative small molecules, particularly relevant to neurodegenerative diseases. the lead compound modifies growth-factor systems, where the activation is expected to stop disease progression and even restore lost function. the company’s research has been funded by the alzheimer’s drug discovery foundation, washington’s life sciences discovery fund, w fund, wrf capital, dolby family ventures and other private investors. where current and emerging therapies are focused primarily on disease symptoms and improving the quality of life of patients suffering from disease, m3 differentiates itself from the competition by addressing the neurodegenerative process, providing a cost-effective solution and feasible delivery mechanism. our strategy is to leverage our patented and proprietary technologies to develop small molecule modulators with a primary focus on altering the course of alzheimer
